The Prediction of Response to Hormonal therapy in advanced and recurrent Endometrial Cancer (PROMOTE) study showed an association between the ER, PR and ER pathway activity (ERPAS) and the outcome [24,28]. Here, PGR is linked to endometrial cancer.